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Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients 
at high risk of cardiovascular events. Among atrial fibrillation (AF) patients, data on LVH, i.e. 
prevalence and determinants, are inconsistent mainly due to different definitions and to 
heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and 
clinical factors independently associated with its development in a prospective cohort of non-
valvular (NV) AF patients. From the ARAPACIS population, 1,184 NVAF patients (mean age 72±11 
years; 56% male) with complete data to define LVH were selected. ARAPACIS is a multicenter, 
observational, prospective, longitudinal on-going study designed to estimate prevalence of 
peripheral artery disease in NVAF patients. We found a high prevalence of LVH (52%) in NVAF 
patients. When compared to those without LVH, AF patients with LVH were older and had a higher 
prevalence of hypertension, diabetes and previous myocardial infarction (MI). A higher prevalence 
of ankle-brachial index (ABI) ≤0.90 was seen in LVH patients (22 vs. 17%, p=0.0392). LVH patients 
were at significantly higher thromboembolic risk, with CHA2DS2-VASc ≥2 seen in 93% of LVH and in 
73% of non-LVH patients (p<0.05). Women with LVH had a higher prevalence of concentric 
hypertrophy than men (46% vs. 29%, p=0.0003). Logistic regression analysis demonstrated that 
female sex (odds ratio (OR): 2.80, p<0.0001), age (OR: 1.03 per year, p<0.001), hypertension (OR: 
2.30, p<0.001), diabetes (OR: 1.62, p=0.004) and previous MI (OR: 1.96, p=0.001) were 
independently associated with LVH.  
In conclusion, NVAF patients have a high prevalence of LVH, which is related to female sex, older 
age, hypertension and prior MI.  These patients are at high thromboembolic risk and deserve a 
holistic approach to cardiovascular prevention. 
  














Atrial Fibrillation (AF) is the most prevalent supraventricular tachyarrhythmia [1,2] associated with 
high risk of death and stroke [3]. Hypertension is the most frequent cardiovascular risk factor in AF 
and recognized as a predictor of new onset AF [4-6].  One of the hypertension-related target organ 
damage is left ventricular hypertrophy (LVH) [7-10]. Data on sex differences in development of 
LVH have been reported in hypertensive patients with [11] or without concomitant heart failure 
[10]. Notwithstanding different definitions and threshold criteria, LVH prevalence ranges widely in 
the general population [10]. Nonetheless, LVH is an independent risk factor for major 
cardiovascular events and all cause death [12-15]. Also, left ventricular remodeling has been 
identified as an independent risk factor for stroke and mortality in AF patients [16]. The aim of our 
study was to determine LVH prevalence, using well-defined echocardiographic criteria based on 
left ventricular mass (LVM) indexed by body surface area (BSA) in a cohort of non-valvular (NV) AF 
patients. Secondly, we aimed to identify the clinical factors independently associated with LVH in 
our patients with NVAF.  Third, we conducted a sex-stratified analysis to investigate relevant sex 
differences in LVH in NVAF patients. 
METHODS 
We performed a cross-sectional analysis on the “Atrial Fibrillation Registry for Ankle-
brachial Index Prevalence Assessment: Collaborative Italian Study” (ARAPACIS) a multicenter, 
observational, prospective on-going study designed to estimate prevalence of Ankle-brachial index 
(ABI) ≤0.90 in NVAF patients and its influence on cardiovascular and cerebro-vascular events 
incidence over a 3 year-follow up. [17,18]. 
Details on standard study procedures have been previously reported [18]. In addition, a 
standard trans-thoracic echocardiography (TTE) [19] was performed where feasible.  Even if a 














echocardiography performed a blinded evaluation of measurements for consistency and 
reliability.  
Patients were consecutively recruited, both as in- or out-patients, if they were ≥18 years 
old and had NVAF diagnosis recorded in the preceding 12 months. Enrollment was performed in 
136 facilities belonging to the Italian Internal Medicine Society (SIMI) network from October 2010 
and continued until 30 October 2012.  All patients signed a written informed consent. The study 
was conducted in accordance with the EU Note for Guidance on Good Clinical Practice 
CPMP/ECH/135/95 and the Declaration of Helsinki.  
Left ventricular mass (LVM) estimation was calculated according to American Society of 
Echocardiography (ASE) and European Association of Echocardiography (EAE) joint 
recommendations [19]. LVM values have been indexed by body-surface area (BSA), calculated 
with the Dubois and Dubois formula (BSA = 0.007184 x weight [Kg]
0.425
 x height [cm]
0.725
). Thus, we 
defined the presence of LVH for a LVM indexed by BSA (LVMI-BSA) > 95 g/m
2
 for women and an 
LVMI-BSA > 115 g/m
2
 for men [19]. 
The definition of LV remodeling was assessed calculating the relative wall thickness (RWT). 
In accordance to ASE/EAE recommendations [19], RWT ≥ 0.42 defined a concentric remodeling, 
otherwise a RWT <0.42 defined an eccentric remodeling. All patients were then categorized into 4 
categories of cardiac remodeling: (I) No Remodeling, i.e. patients without LVH and with a RWT < 
0.42; (II) Concentric Remodeling, i.e. patients without LVH and with a RWT ≥ 0.42; (III) Eccentric 
Hypertrophy, i.e. patients with LVH and a RWT < 0.42; and (IV) Concentric Hypertrophy, i.e. 
patients with LVH and a RWT ≥ 0.42. 
According to Shapiro-Wilk normality test, variables with a normal distribution were tested 
for differences by Student t test and reported as mean±SD. Variables with non-homogeneous 














(IQR). Categorical variables, expressed as counts and percentages, were analyzed by a chi-square 
test. A sex-stratified analysis was also conducted. Finally, a multivariate regression analysis was 
performed in order to establish LVH determinants in NVAF patients. To reduce inter-observer 
variability, the regression analysis was corrected for enrolling centers. The probability values were 
2-sided; a p value <0.05 was considered statistically significant. All analyses were carried out with 
SPSS v.20 (IBM, NY, USA). 
RESULTS 
Among a total of 2,027 patients enrolled in ARAPACIS, echocardiographic data were 
available in 1,184 subjects (59%). After data revision, 1,087 patients (72±11 years; 56% male) were 
eligible for analysis (Figure 1).  Clinical and demographic variables in non-included patients were 
similar to those analyzed (Table 1). 
 Previous cardiovascular disease (CVD) was recorded for about a quarter of patients. Among 
classical cardiovascular risk factors, hypertension was the most prevalent (82%). The mean LVMI-
BSA was 112±31 g/m
2
. Values of LVMI-BSA were higher in permanent NVAF compared to those 
with persistent AF (p=0.0107) or paroxysmal AF (p=0.0023). LVMI-BSA progressively increased 
with higher CHA2DS2-VASc risk classes (p<0.0001) [Figure 2]. 
 LVH was recorded in 52% of patients. Clinical and demographic characteristics among the 
groups are reported in Table 1. LVH patients were older, had a higher prevalence of hypertension, 
diabetes and previous myocardial infarction (MI) compared to those without. ABI≤0.90 was 
prevalent in LVH patients. CHA2DS2-VASc ≥2 class was recorded more frequently in LVH patients. 
Table 2 summarizes echocardiographic characteristics of the 2 groups. LVH patients had 
poorer ventricular function when compared to non-LVH ones. In 59% of LVH patients there was a 














Pharmacologic treatments distribution in the 2 groups, are reported in Table 3. LVH 
patients were more likely treated with oral anticoagulants (OAC) and angiotensin-converting 
enzyme inhibitors (ACEI) than non-LVH ones. 
Final forward logistic model showed that female sex (Odds Ratio [OR]: 2.808, 95% 
Confidence Interval [CI]: 2.152 – 3.664, p<0.001), age (OR per year: 1.035, 95% CI: 1.021 – 1.048, 
p<0.001), hypertension (OR: 2.302, 95% CI: 1.606 – 3.299, p<0.001), diabetes (OR: 1.623, 95% CI: 
1.169 – 2.253, p=0.004) and previous MI (OR: 1.964, 95% CI: 1.328 – 2.903, p=0.001) were 
independently associated with LVH. No influence of enrolling centers was evident.  
LVH was detected in 67% of NVAF women compared to 42% in men. Number of 
atherosclerotic risk factors was higher in male patients with LVH compared to those without 
(2.04±1.20 vs. 1.76±1.02, p=0.0041). Similar data were recorded in LVH female patients compared 
to non-LVH ones (1.92±1.12 vs. 1.70±1.10, p=0.0434). Concentric Hypertrophy was more common 
in female patients (F=46% vs. M=29%, p=0.0003). Women with LVH, compared with men, were 
less treated with OAC (65% vs. 69%, p=0.0318). 
DISCUSSION 
The present analysis of a selected cohort from the ARAPACIS study provides, for the first 
time, data on the high prevalence of LVH, defined as LVM indexed by BSA. Second, we identified 
female sex, age, hypertension, diabetes and previous MI as clinical factors associated with the 
presence of LVH among NVAF patients. Third, we observed that concentric hypertrophy was the 
most common remodeling pattern in female NVAF patients. 
 These findings could contribute to a better understanding of ventricular remodeling among 
patients with NVAF. In fact, previous clinical studies reported a huge range (from 23% to 68%) of 
LVH prevalence in AF [15,16], probably due to heterogeneity of patients enrolled or to different 














provided more reliable data on LVH prevalence among NVAF patients. Second, taking in account 
that LVMI-BSA seems to be one of the most reliable method to determine the cardiovascular risk 
associated with left ventricular remodeling [20], our work could represent a premise for evaluating 
clinical usefulness of LVH detection in cardiovascular risk assessment also in NVAF patients. 
Indeed, higher prevalence of ABI≤0.90 could suggest an association between atherosclerosis and 
LVH [21,22], which requires further investigations. Moreover, the recognition of LVH may play a 
pivotal role to correctly stratify cerebrovascular risk of NVAF patients as reported in hypertensive 
patients [23,24].  In fact previous data demonstrated that increased LVM, as well as abnormal 
RWT, are associated with increased risk of stroke in hypertensive patients, even higher in patients 
with a concentric pattern [24]. 
A post-hoc analysis from the Atrial Fibrillation Follow-up Investigation of Rhythm 
Management (AFFIRM) trial [16] reported that LVH assessed by LVM was an independent 
predictor of both all-cause mortality and stroke among AF patients [16]. Further evaluations of 
follow up data of ARAPACIS study will provide a relevant evidence to clarify this poorly explored 
issue. 
Although LVH patients are at higher thromboembolic risk, we found suboptimal OAC use, 
as previously reported for the overall ARAPACIS study population [17]. Moreover, female LVH 
patients seem to be significantly less treated with OAC. Considering the higher stroke risk in 
women with LVH when compared to men with or without LVH [25,26], the underuse of OAC could 
contribute to the higher stroke risk of female patients.  The standard evaluation of LVH presence 
in NVAF patients could be useful to better define thromboembolic risk, independently by other 
thromboembolism risk factors. When available, prospective data coming from ARAPACIS study 














Our data suggest that different LVH development among sex might be relevant in 
stratifying thromboembolic risks of NVAF patients. The prevalence of concentric hypertrophy in 
our NVAF female patients was significantly higher comparing with men. Indeed, experimental data 
suggest that cardiac hypertrophy development in response to a pathological stimulus may be 
blunted in women compared with men [27], yet the relative mortality risk, when hypertrophy 
does occur, is greater in women and is more commonly concentric [28,29]. As stated above, 
concentric hypertrophy among hypertensive patients carries the greatest stroke risk [24]. 
Furthermore, sex differences in LVH distribution and worse cardiac remodeling in NVAF patients 
may partly explain why female gender confers additional risk of thromboembolic stroke. 
Accordingly, the presence of LVH, as defined by electrocardiography, confers a higher stroke risk 
of in LVH AF patients [15]. 
As with any observational analysis, residual unmeasured confounders may exist and impact 
the validity of our results. Given the cross-sectional nature of the study, data presented cannot 
establish a pathophysiological link between NVAF and LVH, but provide hypothesis-generating 
associations. Given that hypertension was highly prevalent amongst NVAF patients, and since 
hypertension represents a fundamental risk factor for the developing of LVH, we cannot establish 
whether LVH was evident prior to the development of NVAF. Lastly, the present analysis is based 
on the assumption that walls thickness and geometry are homogenous. This assumption could 
bias the evaluation of LVH prevalence, even if reduced by the use of three different measurements 
to assess LVM. 
 To summarize, NVAF patients have a high prevalence of LVH, which is related to female 
sex, older age, hypertension and prior MI. Ongoing prospective data from the ARAPACIS study will 
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Figure 1.  Flow diagram NVAF patient selection 
LVH= left Ventricular Hypertrophy; NVAF= Non-Valvular Atrial Fibrillation.  
 
Figure 2. LVMI-BSA values distribution according to CHA2DS2-VASc score* 














TABLE 1: CLINICAL AND DEMOGRAPHIC CHARACTERISTICS ACCORDING TO THE PRESENCE OF 
LEFT VENTRICULAR HYPERTROPHY 








Yes vs. No 


















Women 439 (47%) 353 (56%) 158 (31%) <0.0001¤ 




28±5 28±5 28±5 0.4876‡ 

















Hypertension* 785 (84%) 515 (89%) 374 (73%) <0.0001¤ 
Diabetes Mellitus 237 (25%) 152 (26%) 77 (15%) <0.0001¤ 
Smoker 138 (15%) 77 (13%) 100 (20%) 0.0057¤ 
Hypercholesterolemia# 353 (38%) 231 (40%) 205 (40%) 0.9964¤ 
Metabolic Syndrome 282 (31%) 164 (30%) 141 (29%) 0.6767¤ 
Previous Transient Ischemic 
Attack/Stroke 
116 (12%) 67 (12%) 52 (10%) 0.4429¤ 
Previous Myocardial 
Infarction 
159 (17%) 105 (18%) 49 (9.6%) <0.0001¤ 
Previous Peripheral Artery 
Disease 
13 (1.4%) 9 (1.4%) 10 (1.9%) 0.5624¤ 
Heart Failure 189 (20%) 102 (18%) 87 (17%) 0.7668¤ 
Ankle-Brachial Index ≤0.90¶ 212 (23%) 128 (22%) 88 (17%) 0.0391¤ 


















Legend: IQR= Interquartile Range; SD= Standard Deviation. 
*Blood Pressure>140/90 mmHg or treated with anti-hypertensive drugs; #Total Cholesterol≥ 240 
mg/dL or treated with lipid lowering drugs; ¶ Data referred to 1,084 patients; ‡ Student t test; ¤ χ
2
 













TABLE 2: ECHOCARDIOGRAPHIC CHARACTERISTICS ACCORDING TO THE PRESENCE OF LEFT 
VENTRICULAR HYPERTROPHY. 
 







Left Ventricular Ejection Fraction (%), 
mean±SD 
54±10 57±8 <0.0001‡ 
Left Ventricular Ejection Fraction <50% 
 
133 (23%) 62 (12%) <0.0001¤ 
Left Ventricular Mass Indexed by  




132±27 89±15 <0.0001‡ 
Relative Wall Thickness (>0.42) 
 
338 (59%) 215 (42%) <0.0001¤ 
Left Ventricular Internal End-Diastolic 
Dimension (mm), mean±SD 
 
 53±6  48±5 <0.0001‡ 
Interventricular Septum Thickness 
(mm), mean±SD 
 
12±2 10±2 <0.0001‡ 
Posterior Wall Thickness (mm), 
mean±SD 
 
11±2 9±1 <0.0001‡ 
Left Atrial Diameter  (mm), mean±SD¶ 
 



















Legend: SD= Standard Deviation. 
















TABLE 3: PHARMACOLOGIC TREATMENTS DISTRIBUTION ACCORDING TO THE PRESENCE OF LEFT 
VENTRICULAR HYPERTROPHY- 
 
























Statins 218 (38%) 189 (37%) 
 
0.7697 





222 (39%) 155 (30%) 
 
0.0045 
Angiotensin II Receptor Blockers 212 (37%) 169 (33%) 
 
0.1979 
Calcium Channel Blockers 165 (29%) 127 (25%) 
 
0.1591 
Nitrates 83 (14%) 38 (7.4%) 
 
0.0002 
Antiarrhythmics 159 (28%) 156 (31%) 
 
0.2888 
Digoxin  117 (20%) 64 (13%) 
 
0.0005 
Diuretics¶ 293 (60%) 193 (45%) 
 
<0.0001 
Oral Hypoglycemic Agents 92 (16%) 52 (10%) 
 
0.0049 
Subcutaneous Insulin 44 (7.6%) 11 (2.1%) 
 
<0.0001 
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